Confirms predictive worth of Nociscan for figuring out painful discs.
Nociscan demonstrated a sensitivity of 100% and a specificity of 80% in comparison with provocative discography (PD), suggesting Nociscan supplies higher info to surgeons.
BROOMFIELD, CO, March 04, 2024 (GLOBE NEWSWIRE) — by way of NewMediaWire — Aclarion, Inc., (“Aclarion” or the “Firm”) (Nasdaq: ACON, ACONW), a healthcare expertise firm that’s leveraging biomarkers and proprietary augmented intelligence algorithms to assist physicians determine the situation of persistent low again ache, introduced right now the publication of the medical paper, Establishing a Gold Customary for Noninvasive Identification of Painful Lumbar Discs: Potential Comparability of Magnetic Resonance Spectroscopy vs Low-Strain Provocation Discography by the Worldwide Journal of Backbone Surgical procedure, the official scientific journal of the Worldwide Society for the Development of Backbone Surgical procedure (ISASS).
Verifying lumbar disc ache has been a medical problem. Low-pressure provocative discography (PD) has served because the gold customary, regardless of well-documented drawbacks together with being extremely invasive and presenting difficult-to-interpret outcomes. Regardless of the small pattern dimension of the research, this newly revealed potential comparability research clearly demonstrates that Nociscan outcomes precisely determine discs which are identified to be painful in keeping with provocative discogram.
Attaining a results of 100% sensitivity (5/5 lumbar discs) signifies that on this research if discography signifies a disc is painful, then Nociscan may also point out that the disc is painful. Then again, with a specificity of 80% (8/10 lumbar discs), which means that when discography signifies a disc is not-painful, Nociscan will disagree 20% of the time by indicating the disc truly incorporates the biomarkers per a painful disc.
The Firm believes it’s this potential of Nociscan to objectively measure ache biomarkers that offers surgeons higher info than discogram to tell their surgical determination making. The Firm additional believes that this differentiation from discogram is the rationale Aclarion was capable of display improved surgical outcomes with Nociscan within the Gornet research.
Ryan Bond, Chief Technique Officer, Aclarion said, “This potential comparability of Nociscan towards the historic benchmark, provocative discography, illustrates highly effective conclusions. The authors of the paper have devoted their careers to advancing the scientific understanding of low again ache pathology, whereas additionally striving to enhance remedy outcomes. This paper provides to Aclarion’s rising physique of proof for Nociscan as offering worthwhile info for the non-invasive identification of painful lumbar discs.”
Aclarion’s proprietary decision-support device, Nociscan, is the primary evidence-supported SaaS platform to non-invasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be related to disc ache. Biomarker information is entered into proprietary algorithms to focus on if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan supplies crucial insights into the situation of a affected person’s low again ache, giving physicians readability to optimize remedy methods.
“In 2023, we revealed the sturdiness of 2-year medical outcomes in an indicator research by Dr. Gornet and others,” mentioned Brent Ness, CEO, Aclarion. “At present’s announcement expands on prior analysis supporting Nociscan and additional advances our said goal to guide with overwhelming proof on our journey to turn into the usual of care inside the low again ache trade. Quickly we are going to launch our nationwide multicenter medical trial, CLARITY, an outcomes research designed to additional consider the position of Nociscan within the prognosis and surgical remedy of sufferers affected by persistent low again ache. We sit up for introducing Nociscan to a rising variety of physicians and sufferers.”
Entry to the publication may be discovered right here.
https://www.ijssurgery.com/content material/early/2024/02/23/8574
Aclarion is sponsoring the upcoming 3rd Annual Sonntag Backbone Symposium, March 22, 2024. Go to us there to be taught extra in regards to the Nociscan resolution.
About Aclarion, Inc.
Aclarion is a healthcare expertise firm that leverages magnetic resonance spectroscopy (MRS), proprietary sign processing strategies, biomarkers, and augmented intelligence algorithms to optimize medical remedies. The Firm is first addressing the persistent low again ache market with Nociscan, the primary, evidence-supported, SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. By a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) information from an MRI machine for every lumbar disc being evaluated. Within the cloud, proprietary sign processing strategies extract and quantify chemical biomarkers demonstrated to be related to disc ache. Biomarker information is entered into proprietary algorithms to point if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan supplies crucial insights into the situation of a affected person’s low again ache, giving physicians readability to optimize remedy methods. For extra info, please go to www.aclarion.com.
Ahead-Wanting Statements
This press launch incorporates forward-looking statements inside the which means of the Non-public Securities Litigation Reform Act of 1995, Part 27A of the Securities Act of 1933 and Part 21E of the Securities Alternate Act of 1934 in regards to the Firm’s present expectations about future outcomes, efficiency, prospects and alternatives. Statements that aren’t historic info, akin to “anticipates,” “believes” and “expects” or related expressions, are forward-looking statements. These forward-looking statements are based mostly on the present plans and expectations of administration and are topic to a variety of uncertainties and dangers that would considerably have an effect on the Firm’s present plans and expectations, in addition to future outcomes of operations and monetary situation. These and different dangers and uncertainties are mentioned extra totally in our filings with the Securities and Alternate Fee. Readers are inspired to evaluation the part titled “Danger Elements” within the Firm’s Annual Report on Kind 10-Ok for the 12 months ended December 31, 2022, in addition to different disclosures contained within the Prospectus and subsequent filings made with the Securities and Alternate Fee. Ahead-looking statements contained on this announcement are made as of this date and the Firm undertakes no obligation to publicly replace or revise any forward-looking statements, whether or not on account of new info, future occasions or in any other case.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
ksmith@pcgadvisory.com
Media Contacts :
Jodi Lamberti
SPRIG Consulting
612.812.7477
jodi@sprigconsulting.com
Discussion about this post